Celldex Therapeutics Inc
Research Celldex Therapeutics Inc (CLDX) on Bullrun: market cap USD 3.24B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLDX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.24B
- Financial periodQ2 2026
- RevenueUSD 22.00K
- Net income-USD 73.50M
- Free cash flow-USD 60.59M
Valuation Snapshot
latest market cap is USD 3.24B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.55M | -USD 258.76M | -USD 213.66M | 87.1% | -3.9 | USD 28.87M | USD 2.34M | USD 527.17M |
| FY2024 | USD 7.02M | -USD 157.86M | -USD 159.70M | 97.2% | -2.45 | USD 28.36M | USD 3.81M | USD 747.01M |
| FY2023 | USD 6.88M | -USD 141.43M | -USD 109.11M | 95.6% | -2.92 | USD 34.81M | USD 2.54M | USD 429.17M |
| FY2022 | USD 2.36M | -USD 112.33M | -USD 105.56M | 95.8% | -2.4 | USD 29.43M | USD 4.01M | USD 326.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.24B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.81B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.68B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.17B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.10B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.81B | n/a | n/a | n/a |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Celldex Therapeutics Inc's market cap?
Celldex Therapeutics Inc's market capitalization is USD 3.24B.
What does Celldex Therapeutics Inc do?
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.